Showing results (141-150 of 292) with videos related to
Sort By:
Pageof 30
Applied Health Economics and Health Policy|April 19, 2025
Compulsory Licensing as an Instrument to Tackle High Medicine Prices: A Realist Review of Industrial and Health ConsequencesSteven Simoens, Walter Van Dyck, Rosanne Janssens, et al.Frontiers in Pharmacology|September 29, 2017
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast CancerEsse I H Akpo, Irshaad R Jansen, Edith Maes, et al.Expert Review of Pharmacoeconomics & Outcomes Research|May 17, 2015
Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013Kim Pauwels, Isabelle Huys, Katelijne De Nys, et al.Regulatory Toxicology and Pharmacology : RTP|January 17, 2015
Causes of drug shortages in the legal pharmaceutical frameworkElfi De Weerdt, Steven Simoens, Luc Hombroeckx, et al.Clinical Therapeutics|February 2, 2015
Reimbursement of targeted cancer therapies within 3 different European health care systemsJovan Mihajlović, Christiaan Dolk, Keith Tolley, et al.Expert Review of Pharmacoeconomics & Outcomes Research|October 5, 2023
Overview and quality assessment of health economic evaluations for homeopathic therapy: an updated systematic reviewThomas Ostermann, Julia Burkart, Sabine De Jaegere, et al.Antimicrobial Agents and Chemotherapy|April 6, 2011
Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolonesSteven Simoens, Jan Verhaegen, Pascal van Bleyenbergh, et al.Applied Health Economics and Health Policy|July 31, 2019
What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian PopulationKim Pauwels, Isabelle Huys, Minne Casteels, et al.Journal of Physical Activity & Health|October 25, 2023
Cost-Utility of an Exercise Referral Scheme Versus Doing Nothing in Flemish Adults: Exploring the Impact of Key AssumptionsAmber Werbrouck, Masja Schmidt, Koen Putman, et al.Health Research Policy and Systems|July 6, 2023
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysisYannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.Pageof 30